Literature DB >> 11115721

CpG DNA is an effective oral adjuvant to protein antigens in mice.

M J McCluskie1, R D Weeratna, A M Krieg, H L Davis.   

Abstract

We have previously reported that synthetic oligodeoxynucleotides containing immunostimulatory CpG motifs (CpG ODN) are potent adjuvants to protein administered by intramuscular (IM) injection or intranasal (IN) inhalation to BALB/c mice. Herein, we have evaluated oral delivery of CpG ODN with purified hepatitis B surface antigen (HBsAg) or tetanus toxoid (TT) to determine its potential as an adjuvant to oral vaccines. CpG ODN augmented systemic (IgG in plasma, CTL, T-cell proliferation) and mucosal (IgA in lung, vaginal or gut washes, feces and saliva) immune responses against both antigens. CpG stimulated both T-helper type 1 (Th1) (CTL, IgG2a) and Th2 (IgG1, IgA) responses when delivered orally. Results from this study indicate that stimulatory CpG ODN may be effective as an adjuvant with oral vaccines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11115721     DOI: 10.1016/s0264-410x(00)00215-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Oral immunization with Porphyromonas gingivalis outer membrane protein and CpGoligodeoxynucleotides elicits T helper 1 and 2 cytokines for enhanced protective immunity.

Authors:  Chenlu Liu; Tomomi Hashizume; Tomoko Kurita-Ochiai; Kohtaro Fujihashi; Masafumi Yamamoto
Journal:  Mol Oral Microbiol       Date:  2010-06       Impact factor: 3.563

Review 2.  Mucosal vaccines: recent progress in understanding the natural barriers.

Authors:  Olga Borges; Filipa Lebre; Dulce Bento; Gerrit Borchard; Hans E Junginger
Journal:  Pharm Res       Date:  2009-12-01       Impact factor: 4.200

3.  CpG DNA assists the whole inactivated H9N2 influenza virus in crossing the intestinal epithelial barriers via transepithelial uptake of dendritic cell dendrites.

Authors:  Y Yin; T Qin; X Wang; J Lin; Q Yu; Q Yang
Journal:  Mucosal Immunol       Date:  2014-12-10       Impact factor: 7.313

4.  Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore.

Authors:  Yuk-Fai Lau; Lay-Hoon Tang; David Chien Lye; Eng-Eong Ooi; Yee-Sin Leo
Journal:  Hum Vaccin Immunother       Date:  2017-02-17       Impact factor: 3.452

5.  Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.

Authors:  J B Knight; Y Y Huang; S A Halperin; R Anderson; A Morris; A Macmillan; T Jones; D S Burt; G Van Nest; S F Lee
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

Review 6.  Novel vaccine development strategies for inducing mucosal immunity.

Authors:  Yoshiko Fujkuyama; Daisuke Tokuhara; Kosuke Kataoka; Rebekah S Gilbert; Jerry R McGhee; Yoshikazu Yuki; Hiroshi Kiyono; Kohtaro Fujihashi
Journal:  Expert Rev Vaccines       Date:  2012-03       Impact factor: 5.217

Review 7.  Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.

Authors:  Kosuke Kataoka; Yoshiko Fukuyama; David E Briles; Tatsuro Miyake; Kohtaro Fujihashi
Journal:  Microbiol Immunol       Date:  2017-06       Impact factor: 1.955

Review 8.  Progress towards a needle-free hepatitis B vaccine.

Authors:  Filipa Lebre; Gerrit Borchard; Maria Conceição Pedroso de Lima; Olga Borges
Journal:  Pharm Res       Date:  2010-11-19       Impact factor: 4.200

9.  Oral pretreatment of mice with CpG DNA reduces susceptibility to oral or intraperitoneal challenge with virulent Listeria monocytogenes.

Authors:  Nancy B Ray; Arthur M Krieg
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

10.  Mucosal immunization with helicobacter, CpG DNA, and cholera toxin is protective.

Authors:  Weiwen Jiang; Henry J Baker; Bruce F Smith
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.